The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats
- PMID: 12417967
- DOI: 10.1007/s00213-002-1259-z
The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats
Abstract
Rationale: A dose-response relationship between dopamine D(2) occupancy and acute extrapyramidal symptoms (EPS) has been well established. However, the link with the induction of tardive dyskinesia (TD) is less clear.
Objectives: To ascertain the nature and extent of D(2) receptor occupancy effects on haloperidol-induced vacuous chewing movements (VCMs) in a rat model of TD.
Methods: Groups of eight rats received haloperidol decanoate injections corresponding to daily doses of 0, 0.08, 0.17, 0.33, or 1 mg/kg for 10-12 weeks. VCMs were measured on a weekly basis and D(2) occupancy levels were measured in vivo using [(3)H]-raclopride at the end of the experiment.
Results: Final VCM scores were significantly different between haloperidol doses ( P=0.001). Moderate but significant correlations were found between dose and average VCM scores (r=0.69, P<0.001) and between D(2) occupancy and average VCM scores (r=0.65, P<0.001). The rats that developed the VCM syndrome (>/=8 VCMs) had higher occupancies than rats that did not. Of the rats with an occupancy above 70%, 63% developed VCMs, compared with 37% of the rats with D(2) occupancy below that.
Conclusions: These results indicate that chronic haloperidol induces VCMs in a dose-dependent manner, with doses leading to high D(2) occupancy increasing the likelihood of emergence of the VCM syndrome. While a certain level of D(2) occupancy may be necessary for inducing VCMs, it is not sufficient in and of itself to induce the VCM syndrome.
Similar articles
-
Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.Synapse. 2004 Dec 1;54(3):156-63. doi: 10.1002/syn.20078. Synapse. 2004. PMID: 15452862
-
Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats.Neuropsychopharmacology. 2003 Aug;28(8):1433-9. doi: 10.1038/sj.npp.1300233. Epub 2003 Jul 2. Neuropsychopharmacology. 2003. PMID: 12838271
-
Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.Pharmacol Biochem Behav. 2007 May;87(1):115-21. doi: 10.1016/j.pbb.2007.04.007. Epub 2007 Apr 13. Pharmacol Biochem Behav. 2007. PMID: 17498786
-
The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?Neurosci Biobehav Rev. 2002 May;26(3):361-80. doi: 10.1016/s0149-7634(02)00008-8. Neurosci Biobehav Rev. 2002. PMID: 12034136 Review.
-
The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia.Mov Disord. 1993 Oct;8(4):445-52. doi: 10.1002/mds.870080405. Mov Disord. 1993. PMID: 7901759 Review.
Cited by
-
Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation.Transl Psychiatry. 2014 Apr 1;4(4):e376. doi: 10.1038/tp.2014.17. Transl Psychiatry. 2014. PMID: 24690597 Free PMC article.
-
Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.J Pharmacol Exp Ther. 2012 Mar;340(3):612-9. doi: 10.1124/jpet.111.189100. Epub 2011 Dec 5. J Pharmacol Exp Ther. 2012. PMID: 22144565 Free PMC article.
-
Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors.J Neurosci. 2004 Sep 22;24(38):8214-22. doi: 10.1523/JNEUROSCI.1274-04.2004. J Neurosci. 2004. PMID: 15385604 Free PMC article.
-
Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice.Neurotox Res. 2024 Dec 19;43(1):2. doi: 10.1007/s12640-024-00724-0. Neurotox Res. 2024. PMID: 39699828
-
Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.Nicotine Tob Res. 2019 Feb 18;21(3):357-369. doi: 10.1093/ntr/nty063. Nicotine Tob Res. 2019. PMID: 30137517 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources